Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population).
This is because the technology is a further treatment option and is available at a similar price.
Tildrakizumab has a discount that is commercial in confidence. For enquiries about the patient access scheme contact: PASUK@almirall.com.
A resource impact template is provided for completion at a local level. This is because there are now several treatment options (biological and non-biological therapies) that are recommended by NICE for plaque psoriasis which can be branded or be a biosimilar.
Therefore, organisations should complete both current and future uptake based on local practice.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts.
This page was last updated: